Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Alvocidib> ?p ?o. }
Showing items 1 to 44 of
44
with 100 items per page.
- Alvocidib abstract "Alvocidib (INN; also known as Flavopiridol or HMR-1275) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia, by Sanofi. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation The target of Flavopiridol is the positive transcription elongation factor P-TEFb. Treatment of cells with Flavopiridol leads to inhibition of P-TEFb and the loss of mRNA production.".
- Alvocidib fdaUniiCode "45AD6X575G".
- Alvocidib iupacName "2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone".
- Alvocidib thumbnail Flavopiridol.svg?width=300.
- Alvocidib wikiPageID "18445946".
- Alvocidib wikiPageRevisionID "604218172".
- Alvocidib hasPhotoCollection Alvocidib.
- Alvocidib imagefile "Flavopiridol.svg".
- Alvocidib imagesize "200".
- Alvocidib iupacname "2".
- Alvocidib unii "45".
- Alvocidib verifiedfields "changed".
- Alvocidib verifiedrevid "457808081".
- Alvocidib subject Category:Chromones.
- Alvocidib subject Category:Experimental_cancer_drugs.
- Alvocidib subject Category:Protein_kinase_inhibitors.
- Alvocidib type Agent114778436.
- Alvocidib type Antineoplastic102722458.
- Alvocidib type CausalAgent100007347.
- Alvocidib type CytotoxicDrug103157987.
- Alvocidib type Drug103247620.
- Alvocidib type ExperimentalCancerDrugs.
- Alvocidib type Inhibitor114724436.
- Alvocidib type Matter100020827.
- Alvocidib type Medicine103740161.
- Alvocidib type PhysicalEntity100001930.
- Alvocidib type ProteinKinaseInhibitors.
- Alvocidib type Substance100020090.
- Alvocidib type ChemicalCompound.
- Alvocidib type ChemicalSubstance.
- Alvocidib type ChemicalSubstanceType.
- Alvocidib type ChemicalObject.
- Alvocidib type Thing.
- Alvocidib comment "Alvocidib (INN; also known as Flavopiridol or HMR-1275) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia, by Sanofi. It has been studied also for the treatment of arthritis and atherosclerotic plaque formation The target of Flavopiridol is the positive transcription elongation factor P-TEFb. Treatment of cells with Flavopiridol leads to inhibition of P-TEFb and the loss of mRNA production.".
- Alvocidib label "Alvocidib".
- Alvocidib label "Альвоцидиб".
- Alvocidib sameAs m.04f3n9d.
- Alvocidib sameAs Q4063441.
- Alvocidib sameAs Q4063441.
- Alvocidib sameAs DB03496.
- Alvocidib sameAs Alvocidib.
- Alvocidib wasDerivedFrom Alvocidib?oldid=604218172.
- Alvocidib depiction Flavopiridol.svg.
- Alvocidib isPrimaryTopicOf Alvocidib.